What is Elicio Therapeutics Inc's primary therapeutic focus and what key cancer targets is it developing immunotherapies against?

Elicio Therapeutics Inc (ELTX) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, specifically targeting mutant KRAS, BRAF, and TP53.

What investment rating and price target has been assigned to Elicio Therapeutics Inc, and what does the target imply about its near-term valuation outlook?

Analysts have given Elicio Therapeutics Inc a 'Buy' rating with a target price of $20.00, representing a significant upside potential, and the company is considered fairly valued despite recent weak market performance.

Elicio Therapeutics Inc Receives 'Buy' Rating with $20 Target

Jul 25, 2026

Elicio Therapeutics Inc, a clinical-stage biotechnology company focusing on cancer immunotherapies, has been given a 'Buy' rating by analysts. Despite recent weak market performance, the stock is considered fairly valued with a target price of $20.00.

TradingKey

2026-06-04

Intrepid Potash Increases Share Repurchase Authorization to $50M

2026-07-25

Elicio Therapeutics Inc Receives 'Buy' Rating with $20 Target

Elicio Therapeutics Inc Receives 'Buy' Rating with $20 Target

FAQ